- Home
- VTYX vs EVG Comparison
VTYX vs EVG Comparison
Compare VTYX & EVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- EVG
- Stock Information
- Founded
- VTYX 2018
- EVG 2005
- Country
- VTYX United States
- EVG United States
- Employees
- VTYX N/A
- EVG N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- EVG Investment Managers
- Sector
- VTYX Health Care
- EVG Finance
- Exchange
- VTYX Nasdaq
- EVG Nasdaq
- Market Cap
- VTYX 154.9M
- EVG 146.4M
- IPO Year
- VTYX 2021
- EVG N/A
- Fundamental
- Price
- VTYX $2.26
- EVG $10.80
- Analyst Decision
- VTYX Buy
- EVG
- Analyst Count
- VTYX 4
- EVG 0
- Target Price
- VTYX $11.33
- EVG N/A
- AVG Volume (30 Days)
- VTYX 2.3M
- EVG 49.4K
- Earning Date
- VTYX 08-07-2025
- EVG 01-01-0001
- Dividend Yield
- VTYX N/A
- EVG 8.68%
- EPS Growth
- VTYX N/A
- EVG N/A
- EPS
- VTYX N/A
- EVG N/A
- Revenue
- VTYX N/A
- EVG N/A
- Revenue This Year
- VTYX N/A
- EVG N/A
- Revenue Next Year
- VTYX N/A
- EVG N/A
- P/E Ratio
- VTYX N/A
- EVG N/A
- Revenue Growth
- VTYX N/A
- EVG N/A
- 52 Week Low
- VTYX $0.78
- EVG $9.13
- 52 Week High
- VTYX $3.39
- EVG $10.86
- Technical
- Relative Strength Index (RSI)
- VTYX 56.94
- EVG 47.01
- Support Level
- VTYX $2.10
- EVG $10.80
- Resistance Level
- VTYX $2.42
- EVG $11.11
- Average True Range (ATR)
- VTYX 0.22
- EVG 0.10
- MACD
- VTYX -0.02
- EVG -0.00
- Stochastic Oscillator
- VTYX 53.99
- EVG 22.50
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About EVG Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest
Eaton Vance Short Duration Diversified Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income with a secondary objective of seeking capital appreciation to the extent consistent with its primary goal. The portfolio of investments consists of business equipment and services, automotive, cable and satellite television, chemicals and plastics, food products, and other areas.